SCHEMBL3537735

SCHEMBL3537735

Brc1ccc2[nH]nc(-c3nc4ccccc4[nH]3)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 11/20 1.00
FGFR1 P11362 3/20 0.71
FLT1 P17948 2/20 0.71
FLT3 P36888 4/20 0.66
CLK4 Q9HAZ1 3/20 0.66
CLK2 P49760 3/20 0.60
DYRK1A Q13627 3/20 0.60
CDK2 P24941 3/20 0.60
MAP4K4 O95819 2/20 0.60
CHEK2 O96017 2/20 0.60
CSF1R P07333 2/20 0.60
FER P16591 2/20 0.60
MARK3 P27448 2/20 0.60
FLT4 P35916 2/20 0.60
CSNK1D P48730 2/20 0.60
CSNK2A1 P68400 2/20 0.60
CSNK1G2 P78368 2/20 0.60
MAP4K2 Q12851 2/20 0.60
STK3 Q13188 2/20 0.60
CAMK2B Q13554 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5951751 0.89 PDPK1 (0.80) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL4918041 0.86 PDPK1 (0.76) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL3533024 0.84 PDPK1 (0.73) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL3538345 0.84 PDPK1 (0.72) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL3534395 0.84 PDPK1 (0.72) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL311148 0.84 FGFR1 (1.00) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL29714859 0.84 FGFR1 (1.00) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL3531870 0.83 PDPK1 (0.71) PDPK1FGFR1FLT1FLT3CLK4
SCHEMBL3537965 0.83 ITK (0.76) PDPK1FGFR1FLT1CDK2CHEK1
SCHEMBL3533017 0.83 PDPK1 (0.71) PDPK1FGFR1FLT1FLT3CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694060-A1 SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE University of Utah Research Foundation (US) 2014-02-12 EP disclosed
US-8569511-B2 Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-10-29 US disclosed
US-8569511-B2 Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-10-29 US disclosed
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION 2012-11-01 US disclosed
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION 2012-11-01 US disclosed
WO-2012135799-A1 SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-10-04 WO disclosed
WO-2012135799-A1 SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-10-04 WO disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK PDPK1 1862/4885FGFR1 886/4885FLT1 2793/4885
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE PDK1, PDK3, PDK2 PDPK1 4/4885FGFR1 961/4885FLT1 2419/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 PDPK1 1896/4885FGFR1 2175/4885FLT1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.